Nolvadex Breast Cancer Prevention Registry Should Be Developed - Cmte.
Executive Summary
FDA should work with Zeneca to develop a Nolvadex (tamoxifen) registry system to track healthy women who are taking the drug to reduce their risk of developing breast cancer, FDA's Oncologic Drugs Advisory Committee recommended Sept. 2.
You may also be interested in...
FDA GI Division Director Justice Is Returning To FDA From Genentech
Genentech Senior Clinical Scientist Robert Justice, MD, is returning to FDA as director of the Division of Gastrointestinal & Coagulation Drug Products in September
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011